Northern Trust Corp Acquires 313,073 Shares of Johnson & Johnson (NYSE:JNJ)

Northern Trust Corp increased its position in Johnson & Johnson (NYSE:JNJ) by 0.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 35,255,462 shares of the company’s stock after purchasing an additional 313,073 shares during the period. Johnson & Johnson comprises about 1.2% of Northern Trust Corp’s investment portfolio, making the stock its 6th biggest holding. Northern Trust Corp’s holdings in Johnson & Johnson were worth $4,910,381,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Johnson & Johnson by 1.7% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,399,820 shares of the company’s stock valued at $1,727,047,000 after buying an additional 209,429 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Johnson & Johnson by 2.6% during the 2nd quarter. Fisher Asset Management LLC now owns 11,841,121 shares of the company’s stock valued at $1,649,231,000 after buying an additional 301,124 shares during the period. Clearbridge Investments LLC boosted its stake in shares of Johnson & Johnson by 0.5% during the 1st quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock valued at $1,345,960,000 after buying an additional 48,582 shares during the period. Nordea Investment Management AB boosted its stake in shares of Johnson & Johnson by 14.2% during the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after buying an additional 1,079,751 shares during the period. Finally, Prudential Financial Inc. boosted its stake in shares of Johnson & Johnson by 8.1% during the 2nd quarter. Prudential Financial Inc. now owns 5,171,858 shares of the company’s stock valued at $720,336,000 after buying an additional 386,047 shares during the period. 72.12% of the stock is owned by hedge funds and other institutional investors.

Shares of JNJ stock traded down $0.31 on Friday, hitting $130.12. The company’s stock had a trading volume of 1,736,477 shares, compared to its average volume of 7,701,360. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The firm’s fifty day moving average price is $130.11 and its 200-day moving average price is $135.97. The stock has a market capitalization of $341.90 billion, a price-to-earnings ratio of 15.91, a P/E/G ratio of 2.19 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the previous year, the business earned $2.10 EPS. Johnson & Johnson’s quarterly revenue was down 1.3% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.92%. The ex-dividend date of this dividend was Monday, August 26th. Johnson & Johnson’s payout ratio is presently 46.45%.

A number of brokerages have issued reports on JNJ. Barclays began coverage on shares of Johnson & Johnson in a research note on Friday, June 21st. They set a “hold” rating and a $140.00 target price for the company. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price for the company. in a research note on Thursday, July 18th. Raymond James reduced their price objective on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research note on Wednesday, July 17th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $150.60.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: What does an equal weight rating mean?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.